October 25, 2014 5:41 AM ET

Healthcare Providers and Services

Company Overview of University Medical Center Utrecht

Company Overview

University Medical Center Utrecht, a public healthcare institution, owns and operates hospitals in the Netherlands. The company focuses on the areas of brain, infection and immunity, circulatory health, personalized cancer care, regenerative medicine and stem cells, and child health. It offers healthcare services in the areas of imaging, biomedical genetics, heart and lungs, surgical specialties, brain, internal medicine and dermatology, pediatrics, laboratories and pharmacy, anesthesiology, intensive care, emergency medicine, and woman and baby. The company also provides healthcare programs and training to students, doctors, researchers, and other healthcare providers. University Medical Ce...

Heidelberglaan 100

Utrecht,  3584 CX

Netherlands

Phone:

31 88 755 5555

Key Executives for University Medical Center Utrecht

President of Executive Board
Secretary
Vice President of Executive Board
Member of Executive Board
Member of Executive Board
Compensation as of Fiscal Year 2014.

University Medical Center Utrecht Key Developments

Stand Up to Cancer, Dutch Cancer Society, American Association for Cancer Research, Hubrecht Institute, University Medical Center Utrecht, Netherlands Cancer Institute, and Wellcome Trust Sanger Institute Announce Formation of Dream Team

Stand Up To Cancer (SU2C) and the Dutch Cancer Society (KWF Kankerbestrijding), along with the American Association for Cancer Research (AACR), SU2Cs scientific partner, announced the formation of a Dream Team dedicated to developing new tools and technologies for preclinical drug testing and analysis. The Sta Op Tegen Kanker (Stand Up To Cancer) Dream Team Translational Cancer Research Grant will provide EUR 6 million ($8.1 million, at the current conversion rate) in funding over four years for this project that will establish a novel, genetically diverse living biobank of patients tumor samples that are maintained and grown in a laboratory, using technology developed by this Dream Team. Called tumor organoids, these growing tumors provide an unprecedented opportunity to investigate the DNA changes that have occurred in these tumors and the consequences of those changes. Importantly, these tumor organoids also will allow researchers to conduct studies of sensitivity and resistance to a large number of anticancer drugs in a laboratory, laying the groundwork for more sophisticated clinical trials that will test treatment regimens specific to the genetic profiles of individual patients and their tumors. Researchers on this Dream Team represent four institutions: the Hubrecht Institute, the University Medical Center Utrecht, the Netherlands Cancer Institute, and the Wellcome Trust Sanger Institute. This Dream Team unites researchers across Europe in a concerted effort to use a groundbreaking new technology to rapidly analyze novel treatment modalities. Hans Clevers, M.D., Ph.D., will lead the Dream Team. Johannes Bos, Ph.D., is the co-leader of the project, which is titled Tumor Organoids: A New Preclinical Model for Drug Sensitivity Analysis.

Similar Private Companies By Industry

Company Name Region
Arseus Dental Solutions BV Europe
Stichting Medisch Centrum Molendael Europe
Pro Persona, GGZ Europe
Tandarts Bemiddelings Bureau B.V. Europe
Pharma Logistics Investments Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University Medical Center Utrecht, please visit www.umcutrecht.nl. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.